Madrigal Pharmaceuticals Inc
MDGL
Company Profile
Business description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Contact
200 Barr Harbor Drive
Suite 200, Four Tower Bridge
West ConshohockenPA19428
USAT: +1 267 824-2827
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
528
Stocks News & Analysis
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
stocks
For US software stocks, it’s been an AI bust, not a boom
Once-hot software names are lagging. Are they good buys?
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.20 | 19.20 | -0.22% |
| CAC 40 | 7,959.67 | 21.40 | -0.27% |
| DAX 40 | 23,464.63 | 225.45 | 0.97% |
| Dow JONES (US) | 47,112.45 | 867.04 | 1.87% |
| FTSE 100 | 9,548.03 | 8.32 | 0.09% |
| HKSE | 25,857.60 | 141.10 | 0.55% |
| NASDAQ | 23,025.59 | 752.51 | 3.38% |
| Nikkei 225 | 48,616.89 | 8.99 | -0.02% |
| NZX 50 Index | 13,576.11 | 95.68 | 0.71% |
| S&P 500 | 6,765.88 | 60.76 | 0.91% |
| S&P/ASX 200 | 8,537.00 | 26.70 | -0.31% |
| SSE Composite Index | 3,871.50 | 34.74 | 0.91% |